<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC3136400/results/search/drugs/results.xml">
  <result pre="treatment of HCV includes pegylated interferon-α (PEG IFN- α) plus" exact="ribavirin" post="(RBV) which has significant side effects depending upon the"/>
  <result pre="standard treatment pegylated interferon-α (PEG IFN- α) in combination with" exact="ribavirin" post="(RBV) have been employed with certain side effects and"/>
  <result pre="in different phases of clinical trials. Debio 025, a non-immunosuppressive" exact="cyclosporine" post="(Cs) analogue, is found to exhibit novel inhibition of"/>
  <result pre="Combined effect of HCV-796 (an NNI of HCV NS5B) and" exact="boceprevir" post="SCH 503034 (an inhibitor of NS3 serine protease) was"/>
  <result pre="for the clinical estimation of three-part combination of PEG IFN-α," exact="boceprevir" post="and HCV-796 [26]. Since RdRp is deficient in proof"/>
  <result pre="or β-D-2'-deoxy-2'-fluoro-2'- C-methylcytidine (2'-F-C-MeC; PSI-6130) with interferon-α 2b (IFN-α2b) plus" exact="ribavirin" post="(RBV) were assessed in subgenomic HCV relicon. β-D-2'-C-methylcytidine (2'-C-MeC;"/>
  <result pre="and different concentrations of compound [32]. High SVR rate of" exact="nitazoxanide" post="along with interferon suggested that nitazoxanide can be exercised"/>
  <result pre="High SVR rate of nitazoxanide along with interferon suggested that" exact="nitazoxanide" post="can be exercised instead of ribavirin to avoid side"/>
  <result pre="with interferon suggested that nitazoxanide can be exercised instead of" exact="ribavirin" post="to avoid side effect of this drug. Another newly"/>
  <result pre="process entailed for the HCVpp entry [71]. Fluphenazine, PCperazine, and" exact="trifluoperazine" post="were currently recognized as inhibitors of HCV entry [64]."/>
  <result pre="HCV entry [64]. These compounds alienated the D2 and D1" exact="dopamine" post="[65,66] and 5-HT2 serotonin receptors [67] in neural signaling"/>
  <result pre="1S385312591185 PoynardTRatziuVMcHutchisonJMannsMGoodmanZZeuzemSYounossiZAlbrechtJEffect of treatment with peginterferon or interferon alfa-2b and" exact="ribavirin" post="on steatosis in patients infected with hepatitis CHepatology200338758512829989 BurloneMEBudkowskaAHepatitis"/>
  <result pre="via clathrin-coated vesiclesJ Virol200680115711157810.1128/JVI.01717-0617005647 FeldJJHoofnagleJHMechanism of action of interferon and" exact="ribavirin" post="in treatment of hepatitis CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients"/>
  <result pre="dually resistant to the polymerase and protease inhibitors HCV-796 and" exact="boceprevir" post="(SCH 503034)Antimicrob Agents Chemother20095340141110.1128/AAC.01081-0818936191 LudmererSWGrahamDJBootsEMurrayEMSimcoeAMarkelEJGroblerJAFloresOAOlsenDBHazudaDJLaFeminaRLReplication fitness and NS5B drug"/>
  <result pre="BassitLGrierJBennettMSchinaziRFCombinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with" exact="ribavirin" post="in the hepatitis C virus replicon systemAntivir Chem Chemother200819253118610555"/>
  <result pre="systemAntivir Chem Chemother200819253118610555 KorbaBEElazarMLuiPRossignolJFGlennJSPotential for hepatitis C virus resistance to" exact="nitazoxanide" post="or tizoxanideAntimicrob Agents Chemother2008524069407110.1128/AAC.00078-0818710916 EinavSSobolHDGehrigEGlennJSThe hepatitis C virus (HCV)"/>
  <result pre="Chemother2008524069407110.1128/AAC.00078-0818710916 EinavSSobolHDGehrigEGlennJSThe hepatitis C virus (HCV) NS4B RNA binding inhibitor" exact="clemizole" post="is highly synergistic with HCV protease inhibitorsJ Infect Dis2026574"/>
  <result pre="virus polymerase that increase RNA binding can confer resistance to" exact="cyclosporine" post="AHepatology200950253310.1002/hep.2298719489073 YangWZhaoYFabryckiJHouXNieXSanchezAPhadkeADeshpandeMAgarwalAHuangMSelection of replicon variants resistant to ACH-806, a"/>
  <result pre="protease inhibitorAntimicrob Agents Chemother2009531377138510.1128/AAC.01058-0819171797 HopkinsSScorneauxBHuangZMurrayMGWringSSmitleyCHarrisRErdmannFFischerGRibeillYSCY-635, a novel nonimmunosuppressive analog of" exact="cyclosporine" post="that exhibits potent inhibition of hepatitis C virus RNA"/>
  <result pre="preclinical speciesBioorg Med Chem1818541865 LawitzERodriguez-TorresMMuirAJKiefferTLMcNairLKhunvichaiAMcHutchisonJGAntiviral effects and safety of telaprevir," exact="peginterferon alfa-2a," post="and ribavirin for 28 days in hepatitis C patientsJ"/>
  <result pre="Chem1818541865 LawitzERodriguez-TorresMMuirAJKiefferTLMcNairLKhunvichaiAMcHutchisonJGAntiviral effects and safety of telaprevir, peginterferon alfa-2a, and" exact="ribavirin" post="for 28 days in hepatitis C patientsJ Hepatol20084916316910.1016/j.jhep.2008.03.02718486984 ShanGZPengZGLiYHLiDLiYPMengSGaoLYJiangJDLiZRA"/>
  <result pre="USA107291296 CaiGGurdalHSmithCWangHYFriedmanEInverse agonist properties of dopaminergic antagonists at the D(1A)" exact="dopamine" post="receptor: uncoupling of the D(1A) dopamine receptor from G(s)"/>
  <result pre="antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A)" exact="dopamine" post="receptor from G(s) proteinMol Pharmacol19995698999610531405 LummisSCBakerJRadioligand binding and photoaffinity"/>
 </snippets>
</snippetsTree>
